David Lane

Om mig
Publikationer
Populärvetenskap och samverkan

Om mig

Professor i tumörsupressorbiologi.

Artiklar

Article: BIOORGANIC & MEDICINAL CHEMISTRY. 2018;26(10):2807-2815

Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges.

Sawyer TK; Partridge AW; Kaan HYK; Juang Y-C; Lim S; Johannes C; Yuen TY; Verma C; Kannan S; Aronica P; Tan YS; Sherborne B; Ha S; Hochman J; Chen S; Surdi L; Peier A; Sauvagnat B; Dandliker PJ; Brown CJ; Ng S; Ferrer F; Lane DP
Article: ONCOGENE. 2018;37(18):2379-2393

p53 isoforms regulate premature aging in human cells.

von Muhlinen N; Horikawa I; Alam F; Isogaya K; Lissa D; Vojtesek B; Lane DP; Harris CC
Article: NATURE COMMUNICATIONS. 2018;9(1):1107

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW; van Leeuwen IMM; Drummond CJ; Chu S; Healy AR; Popova G; Pastor Fernández A; Mollick T; Darekar S; Sedimbi SK; Nekulova M; Sachweh MCC; Campbell J; Higgins M; Tuck C; Popa M; Safont MM; Gelebart P; Fandalyuk Z; Thompson AM; Svensson R; Gustavsson A-L; Johansson L; Färnegårdh K; Yngve U; Saleh A; Haraldsson M; D'Hollander ACA; Franco M; Zhao Y; Håkansson M; Walse B; Larsson K; Peat EM; Pelechano V; Lunec J; Vojtesek B; Carmena M; Earnshaw WC; McCarthy AR; Westwood NJ; Arsenian-Henriksson M; Lane DP; Bhatia R; McCormack E; Laín S
Article: CELL CHEMICAL BIOLOGY. 2018;25(3):309-317.e4

Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate Dehydrogenase.

Costeira-Paulo J; Gault J; Popova G; Ladds MJGW; van Leeuwen IMM; Sarr M; Olsson A; Lane DP; Laín S; Marklund EG; Landreh M
Article: PROTEIN SCIENCE. 2018;27(2):523-530

Evidence for allosteric effects on p53 oligomerization induced by phosphorylation.

Muller P; Chan JM; Simoncik O; Fojta M; Lane DP; Hupp T; Vojtesek B
Article: SCIENTIFIC REPORTS. 2018;8(1):718

The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding.

Lua W-H; Ling W-L; Yeo JY; Poh J-J; Lane DP; Gan SK-E
Article: CELL REPORTS. 2018;22(1):299-312

Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine.

Hwang L-A; Phang BH; Liew OW; Iqbal J; Koh XH; Koh XY; Othman R; Xue Y; Richards AM; Lane DP; Sabapathy K
Article: FRONTIERS IN IMMUNOLOGY. 2018;9:469

Effect of VH-VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding.

Ling W-L; Lua W-H; Poh J-J; Yeo JY; Lane DP; Gan SK-E
Article: PLOS ONE. 2018;13(4):e0195956

Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib.

Ladds MJGW; Pastor-Fernández A; Popova G; van Leeuwen IMM; Eng KE; Drummond CJ; Johansson L; Svensson R; Westwood NJ; McCarthy AR; Tholander F; Popa M; Lane DP; McCormack E; McInerney GM; Bhatia R; Laín S
Article: ONCOTARGET. 2017;8(68):112825-112840

Role of the N-terminal lid in regulating the interaction of phosphorylated MDMX with p53.

Chan JV; Ping Koh DX; Liu Y; Joseph TL; Lane DP; Verma CS; Tan YS
Article: SCIENTIFIC REPORTS. 2017;7(1):15600

Characterizing the conformational landscape of MDM2-binding p53 peptides using Molecular Dynamics simulations.

Yadahalli S; Li J; Lane DP; Gosavi S; Verma CS
Article: BMC BIOLOGY. 2017;15(1):108

A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53.

Wong JH; Alfatah M; Sin MF; Sim HM; Verma CS; Lane DP; Arumugam P
Article: EUROPACE. 2017;19(10):1589-1623

Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE).

Mairesse GH; Moran P; Van Gelder IC; Elsner C; Rosenqvist M; Mant J; Banerjee A; Gorenek B; Brachmann J; Varma N; Glotz de Lima G; Kalman J; Claes N; Lobban T; Lane D; Lip GYH; Boriani G; ESC Scientific Document Group
Article: CANCER RESEARCH. 2017;77(16):4342-4354

Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity.

Zheng S; Koh XY; Goh HC; Rahmat SAB; Hwang L-A; Lane DP
Article: SCIENTIFIC REPORTS. 2017;7(1):1763

Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery.

Thean D; Ebo JS; Luxton T; Lee XC; Yuen TY; Ferrer FJ; Johannes CW; Lane DP; Brown CJ
Article: ONCOGENE. 2017;36(14):2002-2013

The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage.

Xue Y; Raharja A; Sim W; Wong ESM; Rahmat SAB; Lane DP
Article: COLD SPRING HARBOR PERSPECTIVES IN MEDICINE. 2017;7(3):a026310

Exploiting the p53 Pathway for Therapy.

Cheok CF; Lane DP
Article: STRUCTURE. 2017;25(1):188-194

Water-Bridge Mediates Recognition of mRNA Cap in eIF4E.

Lama D; Pradhan MR; Brown CJ; Eapen RS; Joseph TL; Kwoh C-K; Lane DP; Verma CS
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2017;24(1):41-69

Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE.

Mont L; Pelliccia A; Sharma S; Biffi A; Borjesson M; Brugada Terradellas J; Carré F; Guasch E; Heidbuchel H; La Gerche A; Lampert R; McKenna W; Papadakis M; Priori SG; Scanavacca M; Thompson P; Sticherling C; Viskin S; Wilson M; Corrado D; Reviewers; Lip GY; Gorenek B; Blomström Lundqvist C; Merkely B; Hindricks G; Hernández-Madrid A; Lane D; Boriani G; Narasimhan C; Marquez MF; Haines D; Mackall J; Manuel Marques-Vidal P; Corra U; Halle M; Tiberi M; Niebauer J; Piepoli M
Article: EUROPACE. 2017;19(1):139-163

Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE.

Mont L; Pelliccia A; Sharma S; Biffi A; Borjesson M; Terradellas JB; Carré F; Guasch E; Heidbuchel H; Gerche AL; Lampert R; McKenna W; Papadakis M; Priori SG; Scanavacca M; Thompson P; Sticherling C; Viskin S; Wilson M; Corrado D; Lip GYH; Gorenek B; Lundqvist CB; Merkely B; Hindricks G; Hernández-Madrid A; Lane D; Boriani G; Narasimhan C; Marquez MF; Haines D; Mackall J; Marques-Vidal PM; Corra U; Halle M; Tiberi M; Niebauer J; Piepoli M
Article: PLOS ONE. 2017;12(12):e0189379

Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids.

Chee SMQ; Wongsantichon J; Siau J; Thean D; Ferrer F; Robinson RC; Lane DP; Brown CJ; Ghadessy FJ
Article: PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS. 2016;84(10):1443-1461

Reactivation of mutant p53: Constraints on mechanism highlighted by principal component analysis of the DNA binding domain.

Ouaray Z; ElSawy KM; Lane DP; Essex JW; Verma C
Article: JOURNAL OF PHYSICAL CHEMISTRY LETTERS. 2016;7(17):3452-3457

Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design.

Tan YS; Reeks J; Brown CJ; Thean D; Ferrer Gago FJ; Yuen TY; Goh ETL; Lee XEC; Jennings CE; Joseph TL; Lakshminarayanan R; Lane DP; Noble MEM; Verma CS
Article: CELL DEATH AND DIFFERENTIATION. 2016;23(9):1515-1528

p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration.

Turnquist C; Horikawa I; Foran E; Major EO; Vojtesek B; Lane DP; Lu X; Harris BT; Harris CC
Article: SCIENTIFIC REPORTS. 2016;6:23750

Long range recognition and selection in IDPs: the interactions of the C-terminus of p53.

Kannan S; Lane DP; Verma CS
Article: GENES & DEVELOPMENT. 2016;30(3):281-292

The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans.

Coffill CR; Lee AP; Siau JW; Chee SM; Joseph TL; Tan YS; Madhumalar A; Tay B-H; Brenner S; Verma CS; Ghadessy FJ; Venkatesh B; Lane DP
Article: PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS. 2016;84(2):254-266

Wetting of nonconserved residue-backbones: A feature indicative of aggregation associated regions of proteins.

Pradhan MR; Pal A; Hu Z; Kannan S; Chee Keong K; Lane DP; Verma CS
Article: JOURNAL OF PHYSICAL CHEMISTRY B. 2016;120(2):320-328

Recognition Dynamics of p53 and MDM2: Implications for Peptide Design.

ElSawy KM; Lane DP; Verma CS; Caves LSD
Article: PROTEIN ENGINEERING DESIGN & SELECTION. 2016;29(1):11-21

Enhanced antigen detection in immunohistochemical staining using a 'digitized' chimeric antibody.

Eng H-Y; Wang C-I; Xue Y; Lee C-Y; Zulkifli SB; Chiam P-C; Ghadessy FJ; Lane DP
Article: PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS. 2015;83(12):2240-2250

R248Q mutation--Beyond p53-DNA binding.

Ng JWK; Lama D; Lukman S; Lane DP; Verma CS; Sim AYL
Article: ONCOGENE. 2015;34(48):5933-5941

Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish.

Chua JS; Liew HP; Guo L; Lane DP
Article: BIOCHEMISTRY. 2015;54(42):6535-6544

Gating by tryptophan 73 exposes a cryptic pocket at the protein-binding interface of the oncogenic eIF4E protein.

Lama D; Brown CJ; Lane DP; Verma CS
Article: ONCOLOGY REPORTS. 2015;34(4):1692-1700

Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity.

Voon Y-L; Ahmad M; Wong P-F; Husaini R; Ng WT-W; Leong C-O; Lane DP; Khoo AS-B
Article: JOURNAL OF MATERIALS CHEMISTRY B. 2015;3(29):5933-5937

A highly sensitive fluorescent light-up probe for real-time detection of the endogenous protein target and its antagonism in live cells.

Geng J; Goh WL; Zhang C; Lane DP; Liu B; Ghadessy F; Tan YN
Article: ONCOTARGET. 2015;6(20):17968-17980

Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice.

Goh AM; Xue Y; Leushacke M; Li L; Wong JS; Chiam PC; Rahmat SAB; Mann MB; Mann KM; Barker N; Lozano G; Terzian T; Lane DP
Article: SCIENTIFIC REPORTS. 2015;5:12116

Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays.

Tan BX; Brown CJ; Ferrer FJ; Yuen TY; Quah ST; Chan BH; Jansson AE; Teo HL; Nordlund P; Lane DP
Article: CELL DEATH AND DIFFERENTIATION. 2015;22(7):1081-1093

A unique role for p53 in the regulation of M2 macrophage polarization.

Li L; Ng DSW; Mah W-C; Almeida FF; Rahmat SA; Rao VK; Leow SC; Laudisi F; Peh MT; Goh AM; Lim JSY; Wright GD; Mortellaro A; Taneja R; Ginhoux F; Lee CG; Moore PK; Lane DP
Article: CELL RESEARCH. 2015;25(3):351-369

p53 isoform Δ113p53/Δ133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage.

Gong L; Gong H; Pan X; Chang C; Ou Z; Ye S; Yin L; Yang L; Tao T; Zhang Z; Liu C; Lane DP; Peng J; Chen J
Article: CELL CYCLE. 2015;14(2):179-188

A spatiotemporal characterization of the effect of p53 phosphorylation on its interaction with MDM2.

ElSawy KM; Sim A; Lane DP; Verma CS; Caves LS
Article: NPJ BREAST CANCER. 2015;1:15012

A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2.

Lua W-H; Gan SK-E; Lane DP; Verma CS
Article: PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS. 2015;83(1):153-168

mAb806 binding to epidermal growth factor receptor: a computational study.

Ng YZ; Kannan S; Lane DP; Fuentes G; Verma CS
Article: BLOOD TRANSFUSION. 2014;12(4):608-610

Mixed field reactions in ABO and Rh typing chimerism likely resulting from twin haematopoiesis.

Sharpe C; Lane D; Cote J; Hosseini-Maaf B; Goldman M; Olsson ML; Hult AK
Article: CELL DEATH AND DIFFERENTIATION. 2014;21(9):1377-1387

Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response.

Marcel V; Fernandes K; Terrier O; Lane DP; Bourdon J-C
Article: NATURE COMMUNICATIONS. 2014;5:4706

Autophagic degradation of the inhibitory p53 isoform Δ133p53α as a regulatory mechanism for p53-mediated senescence.

Horikawa I; Fujita K; Jenkins LMM; Hiyoshi Y; Mondal AM; Vojtesek B; Lane DP; Appella E; Harris CC
Article: CELL CYCLE. 2014;13(14):2200-2210

Isg15 controls p53 stability and functions.

Huang Y-F; Wee S; Gunaratne J; Lane DP; Bulavin DV
Article: JOURNAL OF CLINICAL INVESTIGATION. 2014;124(7):3263-3273

Phosphatase WIP1 regulates adult neurogenesis and WNT signaling during aging.

Zhu Y; Demidov ON; Goh AM; Virshup DM; Lane DP; Bulavin DV
Article: JOURNAL OF CHEMICAL THEORY AND COMPUTATION. 2014;10(4):1753-1761

Mechanism of Stapled Peptide Binding to MDM2: Possible Consequences for Peptide Design.

Sim AYL; Joseph T; Lane DP; Verma C
Article: JOURNAL OF BIOMOLECULAR SCREENING. 2014;19(4):516-525

The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4.

Yurlova L; Derks M; Buchfellner A; Hickson I; Janssen M; Morrison D; Stansfield I; Brown CJ; Ghadessy FJ; Lane DP; Rothbauer U; Zolghadr K; Krausz E
Article: ONCOTARGET. 2014;5(4):933-943

High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia.

Tan BX; Khoo KH; Lim TM; Lane DP
Article: PLOS ONE. 2014;9(8):e104914

Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.

Chee SMQ; Wongsantichon J; Soo Tng Q; Robinson R; Joseph TL; Verma C; Lane DP; Brown CJ; Ghadessy FJ
Article: CHEMICAL SCIENCE. 2014;5(5):1804-1809

Functionalised staple linkages for modulating the cellular activity of stapled peptides

Lau YH; de Andrade P; Quah S-T; Rossmann M; Laraia L; Skoeld N; Sum TJ; Rowling PJE; Joseph TL; Verma C; Hyvoenen M; Itzhaki LS; Venkitaraman AR; Brown CJ; Lane DP; Spring DR
Article: CELL CYCLE. 2013;12(24):3727-3735

On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein.

ElSawy KM; Verma CS; Lane DP; Caves LSD
Article: SCIENTIFIC REPORTS. 2013;3:3451

Rational optimization of conformational effects induced by hydrocarbon staples in peptides and their binding interfaces.

Lama D; Quah ST; Verma CS; Lakshminarayanan R; Beuerman RW; Lane DP; Brown CJ
Article: BIOSCIENCE REPORTS. 2013;33(6):e00086

A comparison and optimization of methods and factors affecting the transformation of Escherichia coli.

Chan W-T; Verma CS; Lane DP; Gan SK-E
Article: JOURNAL OF CLINICAL INVESTIGATION. 2013;123(12):5247-5257

p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes.

Mondal AM; Horikawa I; Pine SR; Fujita K; Morgan KM; Vera E; Mazur SJ; Appella E; Vojtesek B; Blasco MA; Lane DP; Harris CC
Article: EUROPACE. 2013;15(11):1540-1556

Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.

Kirchhof P; Breithardt G; Aliot E; Al Khatib S; Apostolakis S; Auricchio A; Bailleul C; Bax J; Benninger G; Blomstrom-Lundqvist C; Boersma L; Boriani G; Brandes A; Brown H; Brueckmann M; Calkins H; Casadei B; Clemens A; Crijns H; Derwand R; Dobrev D; Ezekowitz M; Fetsch T; Gerth A; Gillis A; Gulizia M; Hack G; Haegeli L; Hatem S; Häusler KG; Heidbüchel H; Hernandez-Brichis J; Jais P; Kappenberger L; Kautzner J; Kim S; Kuck K-H; Lane D; Leute A; Lewalter T; Meyer R; Mont L; Moses G; Mueller M; Münzel F; Näbauer M; Nielsen JC; Oeff M; Oto A; Pieske B; Pisters R; Potpara T; Rasmussen L; Ravens U; Reiffel J; Richard-Lordereau I; Schäfer H; Schotten U; Stegink W; Stein K; Steinbeck G; Szumowski L; Tavazzi L; Themistoclakis S; Thomitzek K; Van Gelder IC; von Stritzky B; Vincent A; Werring D; Willems S; Lip GYH; Camm AJ
Article: BIOSENSORS & BIOELECTRONICS. 2013;47:421-428

A generic scaffold for conversion of peptide ligands into homogenous biosensors.

Nirantar SR; Yeo KS; Chee S; Lane DP; Ghadessy FJ
Article: MARINE GEOLOGY. 2013;343:15-28

Quantifying overwash flux in barrier systems: An example from Martha's Vineyard, Massachusetts, USA

Carruthers EA; Lane DP; Evans RL; Donnelly JP; Ashton AD
Article: ONCOGENE. 2013;32(34):4009-4016

Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish.

Guo L; Liew HP; Camus S; Goh AM; Chee LL; Lunny DP; Lane EB; Lane DP
Article: GEOCHEMISTRY GEOPHYSICS GEOSYSTEMS. 2013;14(8):2993-3008

Tropical cyclone wind speed constraints from resultant storm surge deposition: A 2500 year reconstruction of hurricane activity from St. Marks, FL

Brandon CM; Woodruff JD; Lane DP; Donnelly JP
Article: ONCOTARGET. 2013;4(7):1019-1036

Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth.

Wong JS; Warbrick E; Vojtesk B; Hill J; Lane DP
Article: ONCOGENE. 2013;32(29):3461-3469

The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell-cycle arrest after DNA damage.

Nicol SM; Bray SE; Black HD; Lorimore SA; Wright EG; Lane DP; Meek DW; Coates PJ; Fuller-Pace FV
Article: ONCOGENE. 2013;32(25):3101-3110

C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances.

Muller P; Ruckova E; Halada P; Coates PJ; Hrstka R; Lane DP; Vojtesek B
Article: CELL RESEARCH. 2013;23(5):620-634

Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation.

Tao T; Shi H; Guan Y; Huang D; Chen Y; Lane DP; Chen J; Peng J
Article: ONCOGENE. 2013;32(17):2150-2160

The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression.

Bernard H; Garmy-Susini B; Ainaoui N; Van Den Berghe L; Peurichard A; Javerzat S; Bikfalvi A; Lane DP; Bourdon JC; Prats A-C
Article: ACS CHEMICAL BIOLOGY. 2013;8(3):506-512

Stapled peptides with improved potency and specificity that activate p53.

Brown CJ; Quah ST; Jong J; Goh AM; Chiam PC; Khoo KH; Choong ML; Lee MA; Yurlova L; Zolghadr K; Joseph TL; Verma CS; Lane DP
Article: ONCOGENE. 2013;32(10):1252-1265

Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.

Muller PAJ; Trinidad AG; Timpson P; Morton JP; Zanivan S; van den Berghe PVE; Nixon C; Karim SA; Caswell PT; Noll JE; Coffill CR; Lane DP; Sansom OJ; Neilsen PM; Norman JC; Vousden KH
Article: CELL CYCLE. 2013;12(3):394-404

On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.

ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LSD
Article: CELL CYCLE. 2013;12(2):278-288

Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9.

Chee JLY; Saidin S; Lane DP; Leong SM; Noll JE; Neilsen PM; Phua YT; Gabra H; Lim TM
Article: METHODS IN MOLECULAR BIOLOGY. 2013;962:15-29

Detecting p53 isoforms at protein level.

Marcel V; Khoury MP; Fernandes K; Diot A; Lane DP; Bourdon J-C
Article: METHODS IN MOLECULAR BIOLOGY. 2013;962:1-14

Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues.

Khoury MP; Marcel V; Fernandes K; Diot A; Lane DP; Bourdon J-C
Article: PLOS ONE. 2013;8(11):e80221

Mapping the structural and dynamical features of multiple p53 DNA binding domains: insights into loop 1 intrinsic dynamics.

Lukman S; Lane DP; Verma CS
Article: DISCOVERY MEDICINE. 2012;14(77):263-271

Seeking synergy in p53 transcriptional activation for cancer therapy.

Cheok CF; Lane DP
Article: TRANSCRIPTION. 2012;3(5):240-244

How p53 wields the scales of fate: arrest or death?

Goh AM; Lane DP
Article: JOURNAL OF VIROLOGY. 2012;86(16):8452-8460

Influenza A viruses control expression of proviral human p53 isoforms p53β and Delta133p53α.

Terrier O; Marcel V; Cartet G; Lane DP; Lina B; Rosa-Calatrava M; Bourdon J-C
Article: HAEMOPHILIA. 2012;18 Suppl 4:141-147

von Willebrand disease biology.

Blombäck M; Eikenboom J; Lane D; Denis C; Lillicrap D
Article: EMBO REPORTS. 2012;13(7):638-644

Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion.

Coffill CR; Muller PAJ; Oh HK; Neo SP; Hogue KA; Cheok CF; Vousden KH; Lane DP; Blackstock WP; Gunaratne J
Article: CELL CYCLE. 2012;11(12):2239-2247

Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding.

Dastidar SG; Lane DP; Verma CS
Article: CELL DEATH AND DIFFERENTIATION. 2012;19(5):816-826

Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity.

Marcel V; Petit I; Murray-Zmijewski F; Goullet de Rugy T; Fernandes K; Meuray V; Diot A; Lane DP; Aberdam D; Bourdon J-C
Article: CELL CYCLE. 2012;11(8):1646-1655

The p53 isoforms are differentially modified by Mdm2.

Camus S; Ménendez S; Fernandes K; Kua N; Liu G; Xirodimas DP; Lane DP; Bourdon J-C
Article: GENES AND CANCER. 2012;3(3-4):320-324

Mdm2 in evolution.

Lane DP; Verma C
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2012;109(5):1685-1690

Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity.

Goh AM; Lim CY; Chiam PC; Li L; Mann MB; Mann KM; Menendez S; Lane DP
Article: JOURNAL OF CHEMICAL THEORY AND COMPUTATION. 2012;8(1):314-321

Characterization of the Ligand Receptor Encounter Complex and Its Potential for in Silico Kinetics-Based Drug Development.

ElSawy KM; Twarock R; Lane DP; Verma CS; Caves LSD
Article: PLOS ONE. 2012;7(10):e47235

Improved eIF4E binding peptides by phage display guided design: plasticity of interacting surfaces yield collective effects.

Zhou W; Quah ST; Verma CS; Liu Y; Lane DP; Brown CJ
Article: PLOS ONE. 2012;7(8):e43985

Stapled BH3 peptides against MCL-1: mechanism and design using atomistic simulations.

Joseph TL; Lane DP; Verma CS
Article: ONCOTARGET. 2011;2(12):1203-1217

Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome.

Neilsen PM; Noll JE; Suetani RJ; Schulz RB; Al-Ejeh F; Evdokiou A; Lane DP; Callen DF
Article: CELL CYCLE. 2011;10(24):4272-4279

Conservation of all three p53 family members and Mdm2 and Mdm4 in the cartilaginous fish.

Lane DP; Madhumalar A; Lee AP; Tay B-H; Verma C; Brenner S; Venkatesh B
Article: THEORETICAL CHEMISTRY ACCOUNTS. 2011;130(4-6):1145-1154

Systematic mutational analysis of an ubiquitin ligase (MDM2)-binding peptide: computational studies

Liu Y; Lane DP; Verma CS
Article: DISCOVERY MEDICINE. 2011;12(63):107-117

New insights into p53 based therapy.

Lane DP; Brown CJ; Verma C; Cheok CF
Article: CELL CYCLE. 2011;10(12):1978-1987

NPMc(+) AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds.

Lew QJ; Tan CH; Gurumurthy M; Chu KL; Cheong N; Lane DP; Chao S-H
Article: CELL CYCLE. 2011;10(7):1100-1108

MDM4 downregulates p53 transcriptional activity and response to stress during differentiation.

Ménendez S; Goh AM; Camus S; Ng KW; Kua N; Badal V; Lane DP
Article: CELL DEATH AND DIFFERENTIATION. 2011;18(2):248-258

p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage.

Aoubala M; Murray-Zmijewski F; Khoury MP; Fernandes K; Perrier S; Bernard H; Prats A-C; Lane DP; Bourdon J-C
Article: JOURNAL OF MOLECULAR BIOLOGY. 2011;405(3):736-753

Stabilizing the eIF4G1 α-helix increases its binding affinity with eIF4E: implications for peptidomimetic design strategies.

Brown CJ; Lim JJ; Leonard T; Lim HCA; Chia CSB; Verma CS; Lane DP
Article: BREAST CANCER RESEARCH. 2011;13(1):R7

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.

Bourdon J-C; Khoury MP; Diot A; Baker L; Fernandes K; Aoubala M; Quinlan P; Purdie CA; Jordan LB; Prats A-C; Lane DP; Thompson AM
Article: CELL CYCLE. 2011;10(1):82-89

Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation.

Dastidar SG; Raghunathan D; Nicholson J; Hupp TR; Lane DP; Verma CS
Article: JOURNAL OF MOLECULAR BIOLOGY. 2010;404(5):819-831

A novel unstructured scaffold based on 4EBP1 enables the functional display of a wide range of bioactive peptides.

See HY; Lane DP
Article: NATURE CELL BIOLOGY. 2010;12(12):1205-1212

Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence.

Fujita K; Horikawa I; Mondal AM; Jenkins LMM; Appella E; Vojtesek B; Bourdon J-C; Lane DP; Harris CC
Article: COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY. 2010;2(12):a000893

p53 Research: the past thirty years and the next thirty years.

Lane D; Levine A
Article: ONCOTARGET. 2010;1(7):639-650

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

Rao B; van Leeuwen IMM; Higgins M; Campbel J; Thompson AM; Lane DP; Lain S
Article: CELL CYCLE. 2010;9(22):4560-4568

Stapled peptides in the p53 pathway: computer simulations reveal novel interactions of the staples with the target protein.

Joseph TL; Lane D; Verma CS
Article: AGING-US. 2010;2(11):748

The p53 inducing drug dosage may determine quiescence or senescence.

Lane DP; Verma C; Fang CC
Article: CHEMISTRY AND BIOLOGY. 2010;17(10):1111-1121

Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.

Wang S; Griffiths G; Midgley CA; Barnett AL; Cooper M; Grabarek J; Ingram L; Jackson W; Kontopidis G; McClue SJ; McInnes C; McLachlan J; Meades C; Mezna M; Stuart I; Thomas MP; Zheleva DI; Lane DP; Jackson RC; Glover DM; Blake DG; Fischer PM
Article: CELL DEATH AND DIFFERENTIATION. 2010;17(9):1486-1500

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.

Cheok CF; Kua N; Kaldis P; Lane DP
Article: COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY. 2010;2(9):a001222

p53-based cancer therapy.

Lane DP; Cheok CF; Lain S
Article: CELL CYCLE. 2010;9(15):3030-3038

Development of a novel multiplex in vitro binding assay to profile p53-DNA interactions.

Goh W; Lane D; Ghadessy F
Article: JOURNAL OF MEDICINAL CHEMISTRY. 2010;53(11):4367-4378

Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.

Wang S; Midgley CA; Scaërou F; Grabarek JB; Griffiths G; Jackson W; Kontopidis G; McClue SJ; McInnes C; Meades C; Mezna M; Plater A; Stuart I; Thomas MP; Wood G; Clarke RG; Blake DG; Zheleva DI; Lane DP; Jackson RC; Glover DM; Fischer PM
Article: CELL CYCLE. 2010;9(10):1998-2007

Detection of the 113p53 protein isoform: a p53-induced protein that feeds back on the p53 pathway to modulate the p53 response in zebrafish.

Guo L; Chua J; Vijayakumar D; Lee KC; Lim K; Eng H; Ghadessy F; Coomber D; Lane DP
Article: CELL CYCLE. 2010;9(6):1167-1181

Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.

Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS
Article: THEORETICAL CHEMISTRY ACCOUNTS. 2010;125(3-6):621-635

Forces mediating protein-protein interactions: a computational study of p53 "approaching" MDM2

Dastidar SG; Madhumalar A; Fuentes G; Lane DP; Verma CS
Article: CELL CYCLE. 2010;9(4):748-754

The Mdm2 and p53 genes are conserved in the Arachnids.

Lane DP; Cheok CF; Brown CJ; Madhumalar A; Ghadessy FJ; Verma C
Article: CELL CYCLE. 2010;9(3):540-547

Mdm2 and p53 are highly conserved from placozoans to man.

Lane DP; Cheok CF; Brown C; Madhumalar A; Ghadessy FJ; Verma C
Article: JOURNAL OF MOLECULAR BIOLOGY. 2010;395(4):871-883

Rational design and biophysical characterization of thioredoxin-based aptamers: insights into peptide grafting.

Brown CJ; Dastidar SG; See HY; Coomber DW; Ortiz-Lombardía M; Verma C; Lane DP
Article: ONCOGENE. 2010;29(3):432-441

MdmX is a substrate for the deubiquitinating enzyme USP2a.

Allende-Vega N; Sparks A; Lane DP; Saville MK
Article: CELL CYCLE. 2009;8(23):3943-3952

Differential scanning fluorimetry as secondary screening platform for small molecule inhibitors of Bcl-XL.

Wan KF; Wang S; Brown CJ; Yu VC; Entzeroth M; Lane DP; Lee MA
Article: CELL CYCLE. 2009;8(17):2828-2836

Design of a novel MDM2 binding peptide based on the p53 family.

Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
Article: NATURE CELL BIOLOGY. 2009;11(9):1135-1142

p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence.

Fujita K; Mondal AM; Horikawa I; Nguyen GH; Kumamoto K; Sohn JJ; Bowman ED; Mathe EA; Schetter AJ; Pine SR; Ji H; Vojtesek B; Bourdon J-C; Lane DP; Harris CC
Article: CELL CYCLE. 2009;8(17):2810-2818

Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.

Choong ML; Yang H; Lee MA; Lane DP
Article: EMBO JOURNAL. 2009;28(14):2100-2113

Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis.

Lee E-W; Lee M-S; Camus S; Ghim J; Yang M-R; Oh W; Ha N-C; Lane DP; Song J
Article: CELL CYCLE. 2009;8(14):2247-2254

Ubiquitination of HEXIM1 by HDM2.

Lau J; Lew QJ; Diribarne G; Michels AA; Dey A; Bensaude O; Lane DP; Chao S-H
Article: CELL CYCLE. 2009;8(12):1905-1911

Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site.

Brown CJ; Verma CS; Walkinshaw MD; Lane DP
Article: JOURNAL OF MEDICINAL CHEMISTRY. 2009;52(9):2673-2682

Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity.

Medda F; Russell RJM; Higgins M; McCarthy AR; Campbell J; Slawin AMZ; Lane DP; Lain S; Westwood NJ
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2009;284(8):5030-5041

Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53.

Dayal S; Sparks A; Jacob J; Allende-Vega N; Lane DP; Saville MK
Article: GENES & DEVELOPMENT. 2009;23(3):278-290

p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish.

Chen J; Ng SM; Chang C; Zhang Z; Bourdon J-C; Lane DP; Peng J
Article: INTERNATIONAL JOURNAL OF CANCER. 2009;124(2):465-472

Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.

Appleyard MVCL; O'Neill MA; Murray KE; Paulin FEM; Bray SE; Kernohan NM; Levison DA; Lane DP; Thompson AM
Article: CELL CYCLE. 2009;8(1):137-148

Dimerization of the core domain of the p53 family: a computational study.

Madhumalar A; Jun LH; Lane DP; Verma CS
Article: CELL CYCLE. 2008;7(23):3759-3767

Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy.

Dey A; Wong E; Kua N; Teo HL; Tergaonkar V; Lane D
Article: CELL CYCLE. 2008;7(21):3417-3427

Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen.

Staples OD; Hollick JJ; Campbell J; Higgins M; McCarthy AR; Appleyard V; Murray KE; Baker L; Thompson A; Ronseaux S; Slawin AMZ; Lane DP; Westwood NJ; Lain S
Article: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 2008;18(21):5771-5773

Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl.

Janssen CO; Lim S; Lo EP; Wan KF; Yu VC; Lee MA; Ng SB; Everett MJ; Buss AD; Lane DP; Boyce RS
Article: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY. 2008;130(41):13514-13515

Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2.

Dastidar SG; Lane DP; Verma CS
Article: BMC CANCER. 2008;8:281

MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.

Paulin FEM; O'Neill M; McGregor G; Cassidy A; Ashfield A; Ali CW; Munro AJ; Baker L; Purdie CA; Lane DP; Thompson AM
Article: ONCOGENE. 2008;27(24):3371-3383

Chaperone-dependent stabilization and degradation of p53 mutants.

Muller P; Hrstka R; Coomber D; Lane DP; Vojtesek B
Article: CANCER CELL. 2008;13(5):454-463

Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

Lain S; Hollick JJ; Campbell J; Staples OD; Higgins M; Aoubala M; McCarthy A; Appleyard V; Murray KE; Baker L; Thompson A; Mathers J; Holland SJ; Stark MJR; Pass G; Woods J; Lane DP; Westwood NJ
Article: JOURNAL OF MOLECULAR BIOLOGY. 2008;378(2):302-317

Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription.

Gurumurthy M; Tan CH; Ng R; Zeiger L; Lau J; Lee J; Dey A; Philp R; Li Q; Lim TM; Price DH; Lane DP; Chao S-H
Article: CLINICAL CANCER RESEARCH. 2008;14(6):1659-1668

Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.

Avery-Kiejda KA; Zhang XD; Adams LJ; Scott RJ; Vojtesek B; Lane DP; Hersey P
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2008;367(2):271-276

Scotin: A new p63 target gene expressed during epidermal differentiation.

Zocchi L; Bourdon JC; Codispoti A; Knight R; Lane DP; Melino G; Terrinoni A
Article: CELL CYCLE. 2008;7(5):608-610

The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides.

Brown CJ; Srinivasan D; Jun LH; Coomber D; Verma CS; Lane DP
Article: CELL DEATH AND DIFFERENTIATION. 2008;15(2):263-273

R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy.

Dey A; Wong ET; Cheok CF; Tergaonkar V; Lane DP
Article: ONCOGENE. 2008;27(5):629-640

Detection of the p53 response in zebrafish embryos using new monoclonal antibodies.

Lee K-C; Goh WLP; Xu M; Kua N; Lunny D; Wong JS; Coomber D; Vojtesek B; Lane EB; Lane DP
Article: CELL CYCLE. 2008;7(1):112-119

Regulation of the p14ARF promoter by DNA methylation.

Badal V; Menendez S; Coomber D; Lane DP
Article: CELL CYCLE. 2007;6(21):2604-2611

Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study.

Lee HJ; Srinivasan D; Coomber D; Lane DP; Verma CS
Article: MOLECULAR CANCER RESEARCH. 2007;5(11):1133-1145

Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.

Cheok CF; Dey A; Lane DP
Article: CELL CYCLE. 2007;6(18):2219-2226

Substrate specificity of cyclins determined by electrostatics.

Lee HJ; Chua GH; Krishnan A; Lane DP; Verma CS
Article: CELL CYCLE. 2007;6(17):2178-2185

Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy.

Dey A; Wong ET; Bist P; Tergaonkar V; Lane DP
Article: JOURNAL OF MOLECULAR BIOLOGY. 2007;371(5):1238-1248

Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization.

Fen CX; Coomber DW; Lane DP; Ghadessy FJ
Article: ONCOGENE. 2007;26(28):4059-4070

Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6.

Camus S; Menéndez S; Cheok CF; Stevenson LF; Laín S; Lane DP
Article: ONCOGENE. 2007;26(11):1517-1521

The p53 knowledgebase: an integrated information resource for p53 research.

Lim YP; Lim TT; Chan YL; Song ACM; Yeo BH; Vojtesek B; Coomber D; Rajagopal G; Lane D
Article: EMBO JOURNAL. 2007;26(4):976-986

The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2.

Stevenson LF; Sparks A; Allende-Vega N; Xirodimas DP; Lane DP; Saville MK
Article: CANCER RESEARCH. 2006;66(6):2928-2936

Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene.

Dudgeon C; Kek C; Demidov ON; Saito S-I; Fernandes K; Diot A; Bourdon J-C; Lane DP; Appella E; Fornace AJ; Bulavin DV
Article: GENES & DEVELOPMENT. 2005;19(23):2900-2911

Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish.

Chen J; Ruan H; Ng SM; Gao C; Soo HM; Wu W; Zhang Z; Wen Z; Lane DP; Peng J
Article: JOURNAL OF PATHOLOGY. 2005;207(3):251-259

Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.

Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
Article: GENES & DEVELOPMENT. 2005;19(18):2122-2137

p53 isoforms can regulate p53 transcriptional activity.

Bourdon J-C; Fernandes K; Murray-Zmijewski F; Liu G; Diot A; Xirodimas DP; Saville MK; Lane DP
Article: INTERNATIONAL JOURNAL OF CANCER. 2005;115(5):701-710

Pilot screening programme for small molecule activators of p53.

Berkson RG; Hollick JJ; Westwood NJ; Woods JA; Lane DP; Lain S
Article: CLINICAL CANCER RESEARCH. 2005;11(13):4875-4887

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
Article: CANCER RESEARCH. 2005;65(12):5399-5407

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.

MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Article: SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND. 2005;3(3):197-205

P53 in cancer: a paradigm for modern management of cancer.

Steele RJC; Lane DP
Article: BLOOD. 2005;105(11):4484-4491

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

Alvi AJ; Austen B; Weston VJ; Fegan C; MacCallum D; Gianella-Borradori A; Lane DP; Hubank M; Powell JE; Wei W; Taylor AMR; Moss PAH; Stankovic T
Article: EMBO JOURNAL. 2005;24(3):543-553

The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor.

Bates GJ; Nicol SM; Wilson BJ; Jacobs A-MF; Bourdon J-C; Wardrop J; Gregory DJ; Lane DP; Perkins ND; Fuller-Pace FV
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2005;102(6):1871-1876

Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design.

Kontopidis G; Wu S-Y; Zheleva DI; Taylor P; McInnes C; Lane DP; Fischer PM; Walkinshaw MD
Article: MOLECULAR CANCER THERAPEUTICS. 2005;4(1):125-139

Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.

Nutley BP; Raynaud FI; Wilson SC; Fischer PM; Hayes A; Goddard PM; McClue SJ; Jarman M; Lane DP; Workman P
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2004;279(48):50157-50166

p14 Arf promotes small ubiquitin-like modifier conjugation of Werners helicase.

Woods YL; Xirodimas DP; Prescott AR; Sparks A; Lane DP; Saville MK
Article: BRITISH JOURNAL OF CANCER. 2004;91(8):1488-1494

Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell level.

Karlsson GB; Jensen A; Stevenson LF; Woods YL; Lane DP; Sørensen MS
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2004;279(40):42169-42181

Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo.

Saville MK; Sparks A; Xirodimas DP; Wardrop J; Stevenson LF; Bourdon J-C; Woods YL; Lane DP
Article: CELL. 2004;118(1):83-97

Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity.

Xirodimas DP; Saville MK; Bourdon J-C; Hay RT; Lane DP
Article: TRENDS IN PHARMACOLOGICAL SCIENCES. 2004;25(7):343-346

Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?

Fischer PM; Lane DP
Article: CHEMISTRY AND BIOLOGY. 2004;11(4):525-534

Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.

McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Article: MOLECULAR CANCER THERAPEUTICS. 2004;3(3):353-362

Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis.

Raynaud FI; Fischer PM; Nutley BP; Goddard PM; Lane DP; Workman P
Article: NEW SCIENTIST. 2004;184(2478):38-41

Dark angel

Lane D
Article: STRUCTURE. 2003;11(12):1537-1546

Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange.

Kontopidis G; Andrews MJI; McInnes C; Cowan A; Powers H; Innes L; Plater A; Griffiths G; Paterson D; Zheleva DI; Lane DP; Green S; Walkinshaw MD; Fischer PM
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2003;278(21):18720-18729

Oligomerization of the human ARF tumor suppressor and its response to oxidative stress.

Menéndez S; Khan Z; Coomber DW; Lane DP; Higgins M; Koufali MM; Lain S
Article: STRUCTURE. 2003;11(4):399-410

Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop.

Wu SY; McNae I; Kontopidis G; McClue SJ; McInnes C; Stewart KJ; Wang S; Zheleva DI; Marriage H; Lane DP; Taylor P; Fischer PM; Walkinshaw MD
Article: BRITISH JOURNAL OF CANCER. 2003;88(4):636-643

Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein.

Menéndez S; Higgins M; Berkson RG; Edling C; Lane DP; Laín S
Article: FEBS LETTERS. 2003;536(1-3):220-224

Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6.

Camus S; Higgins M; Lane DP; Lain S
Article: INTERNATIONAL JOURNAL OF CANCER. 2002;102(5):463-468

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).

McClue SJ; Blake D; Clarke R; Cowan A; Cummings L; Fischer PM; MacKenzie M; Melville J; Stewart K; Wang S; Zhelev N; Zheleva D; Lane DP
Article: CHEMICAL BIOLOGY & DRUG DESIGN. 2002;60(5):257-270

Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.

Zheleva DI; McInnes C; Gavine A-L; Zhelev NZ; Fischer PM; Lane DP
Article: ONCOGENE. 2002;21(43):6624-6632

Cell type-specific responses of human cells to inhibition of replication licensing.

Shreeram S; Sparks A; Lane DP; Blow JJ
Article: FEBS LETTERS. 2002;528(1-3):207-211

P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2.

Xirodimas DP; Chisholm J; Desterro JMS; Lane DP; Hay RT
Article: MOLECULAR AND CELLULAR BIOLOGY. 2002;22(17):6170-6182

Hypophosphorylation of Mdm2 augments p53 stability.

Blattner C; Hay T; Meek DW; Lane DP
Article: HISTOPATHOLOGY. 2002;41(3A):165-171

The assessment of proliferating cell nuclear antigen (PCNA)immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S + G2 + M phase fraction (flow cytometric analysis) and prognosis.

Woods AL; Hall PA; Shepherd NA; Hanby AM; Waseem NH; Lane DP; Levison DA
Article: JOURNAL OF CELL BIOLOGY. 2002;158(2):235-246

Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane.

Bourdon J-C; Renzing J; Robertson PL; Fernandes KN; Lane DP
Article: EMBO REPORTS. 2001;2(11):1029-1034

Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms.

Stad R; Little NA; Xirodimas DP; Frenk R; van der Eb AJ; Lane DP; Saville MK; Jochemsen AG
Article: ONCOGENE. 2001;20(48):7096-7097

Induction of endogenous beta-galactosidase by ionizing radiation complicates the analysis of p53-LacZ transgenic mice.

Coates PJ; Lorimore SA; Rigat BA; Lane DP; Wright EG
Article: ONCOGENE. 2001;20(36):4972-4983

Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.

Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
Article: CANCER LETTERS. 2001;166(2):215-221

Cell differentiation and chemotherapy influence p53 and Mdm2 immunoreactivity in human HT29 colon cancer cells grown in scid mice.

Schumacher U; Adam E; Feldhaus S; Katoh M; Lane DP
Article: EXPERIMENTAL CELL RESEARCH. 2001;265(2):242-251

Use of peptides from p21 (Waf1/Cip1) to investigate PCNA function in Xenopus egg extracts.

Mattock H; Jares P; Zheleva DI; Lane DP; Warbrick E; Blow JJ
Article: EXPERIMENTAL CELL RESEARCH. 2001;265(2):234-241

Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP miniprotein.

Mattock H; Lane DP; Warbrick E
Article: GENE THERAPY. 2001;8(4):274-281

Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53.

Lipinski KS; Djeha AH; Krausz E; Lane DP; Searle PF; Mountain A; Wrighton CJ
Article: MOLECULAR CARCINOGENESIS. 2000;29(4):251-262

p53 is phosphorylated at the carboxyl terminus and promotes the differentiation of human HaCaT keratinocytes.

Paramio JM; Segrelles C; Laín S; Gómez-Casero E; Lane DP; Lane EB; Jorcano JL
Article: NATURE. 2000;408(6810):307-310

Surfing the p53 network.

Vogelstein B; Lane D; Levine AJ
Article: MOLECULAR AND CELLULAR BIOLOGY. 2000;20(22):8458-8467

Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.

Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
Article: CARCINOGENESIS. 2000;21(9):1631-1638

Defective nuclear localization of p53 protein in a Chinese hamster cell line is associated with the formation of stable cytoplasmic protein multimers in cells with gene amplification.

Ottaggio L; Bozzo S; Moro F; Sparks A; Campomenosi P; Miele M; Bonatti S; Fronza G; Lane DP; Abbondandolo A
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2000;97(15):8501-8506

Activation of p53 in cervical carcinoma cells by small molecules.

Hietanen S; Lain S; Krausz E; Blattner C; Lane DP
Article: SURGICAL ONCOLOGY-OXFORD. 2000;9(1):13-16

Gene therapy for gastric cancer: problems and prospects.

Steele RJ; Lane DP
Article: CURRENT BIOLOGY. 2000;10(13):793-796

Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E.

Herbert TP; Fåhraeus R; Prescott A; Lane DP; Proud CG
Article: BIOCHEMISTRY. 2000;39(25):7388-7397

A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics.

Zheleva DI; Zhelev NZ; Fischer PM; Duff SV; Warbrick E; Blake DG; Lane DP
Article: ONCOGENE. 2000;19(19):2312-2323

An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.

Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Article: FEBS LETTERS. 2000;472(1):93-98

Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA.

Burch LR; Midgley CA; Currie RA; Lane DP; Hupp TR
Article: FEBS LETTERS. 1999;463(1-2):179-184

Biochemical characterization of different conformational states of the Sf9 cell-purified p53His175 mutant protein.

Cohen PA; Hupp TR; Lane DP; Daniels DA
Article: EMBO JOURNAL. 1999;18(22):6455-6461

SUMO-1 modification activates the transcriptional response of p53.

Rodriguez MS; Desterro JM; Lain S; Midgley CA; Lane DP; Hay RT
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1999;274(39):28042-28049

Molecular evolution of the thermosensitive PAb1620 epitope of human p53 by DNA shuffling.

Xirodimas DP; Lane DP
Article: EXPERIMENTAL CELL RESEARCH. 1999;248(2):457-472

An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs.

Laín S; Midgley C; Sparks A; Lane EB; Lane DP
Article: MOLECULAR AND CELLULAR BIOLOGY. 1999;19(5):3704-3713

Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53.

Blattner C; Sparks A; Lane D
Article: EMBO JOURNAL. 1999;18(8):2106-2118

The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts.

Fåhraeus R; Lane DP
Article: ONCOGENE. 1999;18(1):189-199

Comparative study of the p53-mdm2 and p53-MDMX interfaces.

Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP
Article: JOURNAL OF PATHOLOGY. 1999;187(1):138-146

New approaches to cancer therapies.

Fåhraeus R; Fischer P; Krausz E; Lane DP
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1998;95(25):14675-14680

Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability.

Nikolova PV; Henckel J; Lane DP; Fersht AR
Article: CARCINOGENESIS. 1998;19(12):2115-2120

Differential expression of p53, p21waf1/cip1 and hdm2 dependent on DNA damage in Bloom's syndrome fibroblasts.

Collister M; Lane DP; Kuehl BL
Article: ONCOGENE. 1998;17(19):2445-2456

Characterization of a new intrabody directed against the N-terminal region of human p53.

Cohen PA; Mani JC; Lane DP
Article: NUCLEIC ACIDS RESEARCH. 1998;26(17):3925-3932

PCNA binding proteins in Drosophila melanogaster : the analysis of a conserved PCNA binding domain.

Warbrick E; Heatherington W; Lane DP; Glover DM
Article: ONCOGENE. 1998;16(5):587-596

Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.

Fåhraeus R; Laín S; Ball KL; Lane DP
Article: JOURNAL OF MOLECULAR BIOLOGY. 1998;275(4):575-588

The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.

Hansen S; Lane DP; Midgley CA
Article: INTERVIROLOGY. 1998;41(1):10-16

Epitope mapping of antibodies recognising the N-terminal domain of simian virus large tumour antigen.

Lindner K; Mole SE; Lane DP; Kenny MK
Article: LANCET. 1998;351:17-20

The promise of molecular oncology

Lane D
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1997;94(26):14338-14342

Thermodynamic stability of wild-type and mutant p53 core domain.

Bullock AN; Henckel J; DeDecker BS; Johnson CM; Nikolova PV; Proctor MR; Lane DP; Fersht AR
Article: CURRENT BIOLOGY. 1997;7(11):860-869

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

Böttger A; Böttger V; Sparks A; Liu WL; Howard SF; Lane DP
Article: TRENDS IN BIOCHEMICAL SCIENCES. 1997;22(10):372-374

MDM2--arbiter of p53's destruction.

Lane DP; Hall PA
Article: ONCOGENE. 1997;15(10):1179-1189

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.

Midgley CA; Lane DP
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1997;272(31):19471-19479

HSP70 binding sites in the tumor suppressor protein p53.

Fourie AM; Hupp TR; Lane DP; Sang BC; Barbosa MS; Sambrook JF; Gething MJ
Article: ONCOGENE. 1997;15(2):237-244

Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential.

Mundt M; Hupp T; Fritsche M; Merkle C; Hansen S; Lane D; Groner B
Article: JOURNAL OF MOLECULAR BIOLOGY. 1997;269(5):744-756

Molecular characterization of the hdm2-p53 interaction.

Böttger A; Böttger V; Garcia-Echeverria C; Chène P; Hochkeppel HK; Sampson W; Ang K; Howard SF; Picksley SM; Lane DP
Article: ONCOGENE. 1997;14(19):2313-2321

Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair.

Warbrick E; Lane DP; Glover DM; Cox LS
Article: JOURNAL OF PATHOLOGY. 1997;181(4):426-433

APC expression in normal human tissues.

Midgley CA; White S; Howitt R; Save V; Dunlop MG; Hall PA; Lane DP; Wyllie AH; Bubb VJ
Article: CURRENT BIOLOGY. 1997;7(3):R144-R147

Tumor suppressors: a developing role for p53?

Hall PA; Lane DP
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1997;272(9):5765-5773

Ku selectively transfers between DNA molecules with homologous ends.

Bliss TM; Lane DP
Article: CURRENT BIOLOGY. 1997;7(1):71-80

Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1.

Ball KL; Lain S; Fâhraeus R; Smythe C; Lane DP
Article: ONCOGENE. 1996;13(12):2575-2587

The p53 response to ionising radiation in adult and developing murine tissues.

MacCallum DE; Hupp TR; Midgley CA; Stuart D; Campbell SJ; Harper A; Walsh FS; Wright EG; Balmain A; Lane DP; Hall PA
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1996;271(48):30922-30928

Modification of two distinct COOH-terminal domains is required for murine p53 activation by bacterial Hsp70.

Hansen S; Midgley CA; Lane DP; Freeman BC; Morimoto RI; Hupp TR
Article: ONCOGENE. 1996;13(10):2141-2147

Identification of novel mdm2 binding peptides by phage display.

Böttger V; Böttger A; Howard SF; Picksley SM; Chène P; Garcia-Echeverria C; Hochkeppel HK; Lane DP
Article: ONCOGENE. 1996;12(11):2461-2466

Epitope analysis of the murine p53 tumour suppressor protein.

Lane DP; Stephen CW; Midgley CA; Sparks A; Hupp TR; Daniels DA; Greaves R; Reid A; Vojtesek B; Picksley SM
Article: METHODS. 1996;9(3):494-507

Phage Peptide Libraries.

Daniels DA; Lane DP
Article: JOURNAL OF CELL SCIENCE. 1996;109 ( Pt 5):1105-1112

Oxidative stress is involved in the UV activation of p53.

Renzing J; Hansen S; Lane DP
Article: FEBS JOURNAL. 1996;237(3):854-861

Human and plant proliferating-cell nuclear antigen have a highly conserved binding site for the p53-inducible gene product p21WAF1.

Ball KL; Lane DP
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1996;271(16):9573-9578

Two pathways for base excision repair in mammalian cells.

Frosina G; Fortini P; Rossi O; Carrozzino F; Raspaglio G; Cox LS; Lane DP; Abbondandolo A; Dogliotti E
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1996;271(9):4954-4960

Modification of an N-terminal regulatory domain of T antigen restores p53-T antigen complex formation in the absence of an essential metal ion cofactor.

Kernohan NM; Hupp TR; Lane DP
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1996;271(7):3917-3924

Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation Group.

Hansen S; Hupp TR; Lane DP
Article: ACTA ONCOLOGICA. 1996;35(4):429-434

The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.

Picksley SM; Spicer JF; Barnes DM; Lane DP
Article: CELL. 1995;83(2):237-245

Small peptides activate the latent sequence-specific DNA binding function of p53.

Hupp TR; Sparks A; Lane DP
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1995;270(30):18165-18174

Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner.

Hupp TR; Lane DP
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1995;6(6):1319-1323

The expression of p53 tumor-suppressor protein during progression of gastric and colorectal carcinomas.

Starzynska T; Bromley M; Lane D; Stern P
Article: BRITISH JOURNAL OF CANCER. 1995;71(6):1253-1256

Absence of p53 autoantibodies in a significant proportion of breast cancer patients.

Vojtesek B; Kovarik J; Dolezalova H; Nenutil R; Havlis P; Brentani RR; Lane DP
Article: EMBO JOURNAL. 1995;14(9):2099-2105

A direct effect of activated human p53 on nuclear DNA replication.

Cox LS; Hupp T; Midgley CA; Lane DP
Article: BRITISH JOURNAL OF CANCER. 1995;71(5):1013-1017

Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.

Borg A; Lennerstrand J; Stenmark-Askmalm M; Fernö M; Brisfors A; Ohrvik A; Stål O; Killander D; Lane D; Brundell J
Article: JOURNAL OF CELL SCIENCE. 1995;108 ( Pt 5):1843-1848

Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo.

Midgley CA; Owens B; Briscoe CV; Thomas DB; Lane DP; Hall PA
Article: CURRENT BIOLOGY. 1995;5(3):275-282

A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen.

Warbrick E; Lane DP; Glover DM; Cox LS
Article: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES. 1995;347(1319):83-87

On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage.

Lane DP; Midgley CA; Hupp TR; Lu X; Vojtesek B; Picksley SM
Visa fler

Alla övriga publikationer

Review: NATURE REVIEWS CLINICAL ONCOLOGY. 2018;15(1):13-30

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Sabapathy K; Lane DP
Review: JOURNAL OF MOLECULAR CELL BIOLOGY. 2017;9(1):3-15

Anatomy of Mdm2 and Mdm4 in evolution.

Tan BX; Liew HP; Chua JS; Ghadessy FJ; Tan YS; Lane DP; Coffill CR
Review: DRUG DISCOVERY TODAY. 2016;21(10):1642-1653

Stapled peptide design: principles and roles of computation.

Tan YS; Lane DP; Verma CS
Corrigendum: NATURE REVIEWS DRUG DISCOVERY. 2014;13(4):314

Drugging the p53 pathway: understanding the route to clinical efficacy (vol 13, pg 217, 2014)

Khoo KH; Verma CS; Lane DP
Review: NATURE REVIEWS DRUG DISCOVERY. 2014;13(3):217-236

Drugging the p53 pathway: understanding the route to clinical efficacy.

Khoo KH; Verma CS; Lane DP
Other: CELL CYCLE. 2012;11(8):1488-1489

Stress, specificity and the NEDD8 proteome.

Lane DP
Review: EUROPACE. 2012;14(1):8-27

Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference.

Kirchhof P; Lip GYH; Van Gelder IC; Bax J; Hylek E; Kaab S; Schotten U; Wegscheider K; Boriani G; Brandes A; Ezekowitz M; Diener H; Haegeli L; Heidbuchel H; Lane D; Mont L; Willems S; Dorian P; Aunes-Jansson M; Blomstrom-Lundqvist C; Borentain M; Breitenstein S; Brueckmann M; Cater N; Clemens A; Dobrev D; Dubner S; Edvardsson NG; Friberg L; Goette A; Gulizia M; Hatala R; Horwood J; Szumowski L; Kappenberger L; Kautzner J; Leute A; Lobban T; Meyer R; Millerhagen J; Morgan J; Muenzel F; Nabauer M; Baertels C; Oeff M; Paar D; Polifka J; Ravens U; Rosin L; Stegink W; Steinbeck G; Vardas P; Vincent A; Walter M; Breithardt G; Camm AJ
Corrigendum: NATURE REVIEWS CLINICAL ONCOLOGY. 2011;8(10):568

Translating p53 into the clinic (vol 8, pg 25, 2011)

Cheok CF; Verma CS; Baselga J; Lane DP
Review: JOURNAL OF PATHOLOGY. 2011;223(2):116-126

The role of mutant p53 in human cancer.

Goh AM; Coffill CR; Lane DP
Review: NATURE REVIEWS CLINICAL ONCOLOGY. 2011;8(1):25-37

Translating p53 into the clinic.

Cheok CF; Verma CS; Baselga J; Lane DP
Review: TRENDS IN PHARMACOLOGICAL SCIENCES. 2011;32(1):53-62

Reactivation of p53: from peptides to small molecules.

Brown CJ; Cheok CF; Verma CS; Lane DP
Corrigendum: CELL CYCLE. 2010;9(19):4031

Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site (vol 8, pg 1905, 2009)

Brown CJ; Verma CS; Walkinshaw MD; Lane DP
Editorial comment: CANCER CELL. 2010;18(3):201-202

SNPing Away at Cancer.

Goh AM; Lane DP
Editorial comment: JOURNAL OF PATHOLOGY. 2010;220(4):401-403

p53 transcriptional pathways in breast cancer: the good, the bad and the complex.

Thompson AM; Lane DP
Published conference paper: BMC GENOMICS. 2010;11 Suppl 1(Suppl 1):S5

Differences in the transactivation domains of p53 family members: a computational study.

Mavinahalli JN; Madhumalar A; Beuerman RW; Lane DP; Verma C
Review: SEMINARS IN CANCER BIOLOGY. 2010;20(1):3-9

Modulating the p53 pathway.

Dey A; Lane DP; Verma CS
Published conference paper: BMC BIOINFORMATICS. 2009;10 Suppl 15(Suppl 15):S6

Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100.

Dastidar SG; Lane DP; Verma CS
Review: NATURE REVIEWS CANCER. 2009;9(12):862-873

Awakening guardian angels: drugging the p53 pathway.

Brown CJ; Lain S; Verma CS; Fersht AR; Lane DP
Review: NATURE REVIEWS DRUG DISCOVERY. 2008;7(12):1031-1040

Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways.

Dey A; Tergaonkar V; Lane DP
Other: CELL CYCLE. 2008;7(21):3287-3291

Targeting a nucleolar SUMO protease for degradation A mechanism by which ARF induces SUMO conjugation

Xirodimas DP; Lane DP
Review: DRUG DEVELOPMENT RESEARCH. 2008;69(6):289-296

New Developments in Small Molecules Targeting p53 Pathways in Anticancer Therapy

Cheok CF; Lane DP
Review: BRITISH JOURNAL OF CANCER. 2008;98(1):4-8

Updates on p53: modulation of p53 degradation as a therapeutic approach.

Dey A; Verma CS; Lane DP
Review: NATURE REVIEWS MOLECULAR CELL BIOLOGY. 2007;8(4):275-283

p53 in health and disease.

Vousden KH; Lane DP
Editorial comment: NATURE BIOTECHNOLOGY. 2006;24(2):163-164

Designer combination therapy for cancer.

Lane D
Review: BRITISH JOURNAL OF CANCER. 2005;92(3):434-444

P53 abnormalities and outcomes in colorectal cancer: a systematic review.

Munro AJ; Lain S; Lane DP
Review: COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY. 2005;70:489-497

Exploiting the p53 pathway for the diagnosis and therapy of human cancer.

Lane DP
Review: NATURE REVIEWS CANCER. 2004;4(9):727-737

Transcription - guarding the genome by sensing DNA damage.

Ljungman M; Lane DP
Editorial comment: CARCINOGENESIS. 2004;25(7):1077-1081

Anthony Dipple Carcinogenesis Award. p53 from pathway to therapy.

Lane D
Editorial comment: NEW ENGLAND JOURNAL OF MEDICINE. 2004;350(26):2711-2712

Curing cancer with p53.

Lane D
Editorial comment: NATURE. 2004;427(6977):789-790

Turning the key on p53.

Lane DP; Fischer PM
Review: MINI-REVIEWS IN MEDICINAL CHEMISTRY. 2003;3(3):257-270

The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.

Zheleva DI; Lane DP; Fischer PM
Editorial comment: CELL DEATH AND DIFFERENTIATION. 2003;10(4):397-399

p53: 25 years of research and more questions to answer.

Bourdon JC; Laurenzi VD; Melino G; Lane D
Review: BRITISH JOURNAL OF SURGERY. 2003;85(11):1460-1467

The p53 tumour suppressor gene.

Steele RJ; Thompson AM; Hall PA; Lane DP
Review: HEMATOLOGY JOURNAL. 2003;4(4):233-247

Exploiting the p53 pathway for cancer diagnosis and therapy.

Woods YL; Lane DP
Review: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. 2003;3(1):57-69

Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.

McInnes C; Andrews MJI; Zheleva DI; Lane DP; Fischer PM
Editorial comment: TRENDS IN CELL BIOLOGY. 2002;12(12):541-542

'Mind the gap'.

Lane DP
Review: TRENDS IN MOLECULAR MEDICINE. 2002;8(4 Suppl):S38-S42

Therapeutic exploitation of the p53 pathway.

Lane DP; Lain S
Review: JOURNAL OF MOLECULAR BIOLOGY. 2001;313(4):711-731

Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.

Liu WL; Midgley C; Stephen C; Saville M; Lane DP
Review: BIOCONJUGATE CHEMISTRY. 2001;12(6):825-841

Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation.

Fischer PM; Krausz E; Lane DP
Editorial comment: NATURE. 2001;414(6859):25-27

How cells choose to die.

Lane D
Review: CURRENT MEDICINAL CHEMISTRY. 2000;7(12):1213-1245

Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.

Fischer PM; Lane DP
Review: BIOCHEMICAL JOURNAL. 2000;352 Pt 1(Pt 1):1-17

Strategies for manipulating the p53 pathway in the treatment of human cancer.

Hupp TR; Lane DP; Ball KL
Editorial comment: CHEMICAL BIOLOGY & DRUG DESIGN. 2000;55(2):163-172

Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin.

Fischer PM; Zhelev NZ; Wang S; Melville JE; Fåhraeus R; Lane DP
Review: EXPERIMENTAL CELL RESEARCH. 1999;253(2):315-324

Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function.

Laín S; Xirodimas D; Lane DP
Editorial comment: JOURNAL OF PATHOLOGY. 1999;187(1):2-3

Preface to molecular and cellular themes in cancer research

Hall PA; Lane DP
Editorial comment: NATURE MEDICINE. 1998;4(9):1012-1013

Killing tumor cells with viruses--a question of specificity.

Lane DP
Editorial comment: NATURE. 1998;394(6694):616-617

Awakening angels.

Lane D
Editorial comment: JOURNAL OF PATHOLOGY. 1996;180(1):1-5

p53--integrating the complexity.

Hall PA; Meek D; Lane DP
Other: COMPTES RENDUS BIOLOGIES. 1995;318(11):1173-1179

Cancer: the translation of advances in basic science to human therapy. 22-27 July 1995. La fondation des Treilles, Tourtour France.
Review: BIOESSAYS. 1995;17(6):501-508

Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage.

Cox LS; Lane DP
Other: ONCOGENE. 1995;10(9):1865-1868

p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts.

Renzing J; Lane DP
Review: JOURNAL OF MOLECULAR BIOLOGY. 1995;248(1):58-78

Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions.

Stephen CW; Helminen P; Lane DP
Editorial comment: NATURE GENETICS. 1995;9(3):221-222

The dominating effect of mutant p53.

Hann BC; Lane DP
Other: ONCOGENE. 1995;10(2):389-393

Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.

Vojtesek B; Dolezalova H; Lauerova L; Svitakova M; Havlis P; Kovarik J; Midgley CA; Lane DP
Visa fler

Om mig

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI